Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Fibrocell Science Inc. (NASDAQ: FCSC).

Full DD Report for FCSC

You must become a subscriber to view this report.


Recent News from (NASDAQ: FCSC)

Fibrocell Announces Oral Presentation at 7th International Investigative Dermatology Meeting
EXTON, Pa., May 16, 2018 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ:FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, today announced that an abstract will be presented in an oral session at the 7 th ...
Source: GlobeNewswire
Date: May, 16 2018 16:05
Fibrocell Science's (FCSC) CEO John Maslowski on Q1 2018 Results - Earnings Call Transcript
Fibrocell Science, Inc. (FCSC) Q1 2018 Results Earnings Conference Call May 10, 2018 08:30 AM ET Executives Karen Casey - IR, Manager John Maslowski - President and CEO Analysts Joe Pantginis - H.C. Wainwright Keith Markey - Griffin Securities Presentation Operator ...
Source: SeekingAlpha
Date: May, 10 2018 11:24
Fibrocell Reports First Quarter 2018 Financial Results and Recent Highlights
EXTON, Pa., May 10, 2018 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ:FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, today reported financial results for the first quarter ended March 31, 2018 and rec...
Source: GlobeNewswire
Date: May, 10 2018 08:00
Fibrocell to Host Conference Call and Webcast on Thursday, May 10, 2018 to Discuss First Quarter 2018 Financial Results and Recent Highlights
EXTON, Pa., May 03, 2018 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ:FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, will report financial results for the first quarter ended March 31, 2018 and recent...
Source: GlobeNewswire
Date: May, 03 2018 08:00
Fibrocell Science to explore strategic alternatives
Fibrocell Science (NASDAQ: FCSC ) announces that it will commence a comprehensive review of strategic alternatives aimed at boosting shareholder value. Canaccord Genuity LLC is advising. More news on: Fibrocell Science, Inc., Healthcare stocks news, Stocks on the move, Read more ...
Source: SeekingAlpha
Date: April, 18 2018 08:24
Fibrocell Announces Review of Strategic Alternatives
EXTON, Pa., April 18, 2018 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ:FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, today announced that its Board of Directors is conducting a comprehensive review ...
Source: GlobeNewswire
Date: April, 18 2018 08:00
Fibrocell to Present at 6th Annual Cell & Gene Therapy Investor Day and 2018 World Orphan Drug Congress USA
EXTON, Pa., April 10, 2018 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ:FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, today announced that John Maslowski, President and Chief Executive Officer, will ...
Source: GlobeNewswire
Date: April, 10 2018 08:00
Novartis takeout of AveXis stokes buying in gene therapy players
Gene therapy developers bluebird bio (NASDAQ: BLUE ) and Audentes Therapeutics (NASDAQ: BOLD ) are up  8%  and  10%  premarket, respectively, both on light volume on the heels of Novartis' $8.7B bid for AveXis. More news on: bluebird bio, Inc., Audentes Therapeutics, In...
Source: SeekingAlpha
Date: April, 09 2018 07:19
Fibrocell Science's (FCSC) CEO John Maslowski on Q4 2017 Results - Earnings Call Transcript
Fibrocell Science, Inc. (FCSC) Q4 2017 Earnings Conference Call March 19, 2018 08:30 AM ET Executives Karen Casey - Manager, Investor Relations John Maslowski - President and Chief Executive Officer Analysts Joe Pantginis - H.C. Wainwright Keith Markey - Griffin Securities ...
Source: SeekingAlpha
Date: March, 19 2018 13:40
Fibrocell Science reports Q4 results
Fibrocell Science (NASDAQ: FCSC ): Q4 EPS of -$1.33 Cash and cash equivalents of $17.42M Press Release More news on: Fibrocell Science, Inc., Earnings news and commentary, Healthcare stocks news, ,
Source: SeekingAlpha
Date: March, 19 2018 08:08

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-08-172.012.002.031.9839,071
2018-08-162.042.032.081.969969,809
2018-08-152.082.02412.081.970343,958
2018-08-142.112.082.162.0473,457
2018-08-132.102.102.34832.0161,726

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-172,88826,15811.0406Cover
2018-08-168,27424,66933.5401Cover
2018-08-157,44425,25429.4765Cover
2018-08-149,22617,71152.0919Short
2018-08-138,02525,14431.9162Cover

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on FCSC.


About Fibrocell Science Inc. (NASDAQ: FCSC)

Logo for Fibrocell Science Inc. (NASDAQ: FCSC)

Not available

 

Contact Information

 

 

Current Management

  • David Pernock / CEO
  • Declan Daly / COO, CFO
  • George J. Korkos /

Current Share Structure

  • Market Cap: $16,968,440 - 05/16/2018
  • Issue and Outstanding: 28,356,351 - 03/06/2018

 


Recent Filings from (NASDAQ: FCSC)

Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 10 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 10 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 18 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 02 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: April, 02 2018
Preliminary proxy statement providing notification matters to be brought to a vote
Filing Type: PRE 14AFiling Source: edgar
Filing Date: March, 19 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 19 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: March, 19 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 06 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 13 2018

 

 


Daily Technical Chart for (NASDAQ: FCSC)

Daily Technical Chart for (NASDAQ: FCSC)


Stay tuned for daily updates and more on (NASDAQ: FCSC)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: FCSC)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in FCSC is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of FCSC and does not buy, sell, or trade any shares of FCSC. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/